Compare iShares Semiconductor ETF (SOXX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Semiconductor ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Semiconductor ETF trades at $559.4 (market cap $48.19B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: iShares Semiconductor ETF is far larger — about 4.8× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 10,257,578). Which is the better fit depends on your goals — on Pluang, investors hold iShares Semiconductor ETF for 46 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SOXX | XBI | |
|---|---|---|
Market Cap | $48.19B | $10.11B |
Volume | 10,257,578 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $655.01 | $169.55 |
52-Week Low | $268.10 | $104.99 |
Typical Hold Time | 46 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXX trades at $563.28, down 3.37% on the day, with bullish technical signals from moving averages and a neutral oscillator reading. The ETF faces mixed sentiment with positive AI-driven earnings momentum countered by valuation concerns and Michael Burry's expanded short positions. Recent news highlights strong September performance driven by chip stock gains and AI infrastructure demand projections.
The semiconductor ETF's outlook hinges on sustained AI demand growth versus elevated valuations. BofA projects the global chip market to nearly double by 2030, providing fundamental support, but concentration risk and potential multiple compression present headwinds. Earnings growth remains the key catalyst for further upside from current levels.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
